Condition: Glioblastoma · Sponsor: Centre Paul Strauss
ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.
This description comes directly from the study's public registry record.
Anne ANTHONY · (0)388252413 · promotion-rc@institut-strauss.fr
MANON VOEGELIN · (0)3 68 33 95 23 · promotion-rc@institut-strauss.fr
Always discuss trial participation with your own doctor first.
| CHRU de Nancy | Nancy, De, France | Not Yet Recruiting |
| Centre Paul Strauss | Strasbourg, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05653635